The Growth Hormone Axis: GHRH, Somatostatin, and GH Secretagogues

Compiled by the APL Research TeamSourced directly from peer-reviewed pharmacological literature and clinical guidelines.

Key Takeaways

• Expert Insight: A comprehensive guide to the hypothalamic-pituitary growth hormone axis, covering GHRH signalling, somatostatin inhibition, the ghrelin/GHS receptor, and how research peptides interact with this system.
• Quality Assurance: All discussed methodologies align with stringent Australian laboratory standards.
• Clinical Relevance: Critical informational resource for verifying the stability and purity of the growth hormone axis: ghrh, somatostatin, and gh secretagogues in-vitro.

Introduction

The growth hormone (GH) axis — formally the hypothalamic-pituitary-somatotroph axis — is a neuroendocrine system that regulates GH secretion, body composition, metabolism, and tissue growth. Understanding this axis is essential for interpreting research involving GHRH analogs (tesamorelin, CJC-1295) and GH secretagogues (ipamorelin), as these peptides interact with specific nodes of the regulatory network.

This article provides a systems-level overview of the GH axis, from hypothalamic regulation through pituitary secretion to peripheral actions and feedback.

Axis Architecture

The GH axis operates through a three-tier hierarchical system:

Tier 1: Hypothalamus (Regulatory)

Two hypothalamic peptides provide opposing control:

• GHRH (Growth Hormone Releasing Hormone) — produced in the arcuate nucleus; stimulates GH synthesis and secretion
• Somatostatin (SST, GHIH) — produced in the periventricular nucleus; inhibits GH release

The balance between GHRH and somatostatin determines the pulsatile pattern of GH secretion. GHRH and SST are released in alternating phases, creating "windows" of GH release (high GHRH, low SST) and GH suppression (low GHRH, high SST).

A third input — ghrelin (produced primarily in the stomach) — acts as a modulator, amplifying GH pulses via the GHS-R1a receptor on both hypothalamic neurons and pituitary somatotrophs.

Tier 2: Anterior Pituitary (Secretory)

Somatotroph cells in the anterior pituitary:

• Express both GHRH receptors and somatostatin receptors (SST subtypes 2 and 5 primarily)
• Also express GHS-R1a (ghrelin/GHS receptor)
• Integrate the stimulatory (GHRH, ghrelin/GHS) and inhibitory (SST) signals
• Synthesise, store, and secrete GH in response to the net signal balance

Tier 3: Periphery (Effector and Feedback)

GH acts on target tissues through two main pathways:

• Direct GH actions — lipolysis, glucose modulation, immune function
• IGF-1 mediated actions — growth, anabolic effects, tissue repair (GH stimulates hepatic IGF-1 production)

The lipolytic activity of the direct pathway has been mapped in preclinical work to a C-terminal region of the GH molecule rather than the intact hormone, which is the basis for research on the isolated fragment — see our AOD-9604 growth hormone fragment guide.

Both GH and IGF-1 feed back to the hypothalamus and pituitary, completing the regulatory loop.

The Pulsatile Pattern

GH is not secreted continuously. Instead, it is released in discrete pulses with the following characteristics:

• Pulse frequency: 6-12 major pulses per 24 hours
• Pulse amplitude: Variable; largest pulses occur during slow-wave sleep
• Trough levels: GH falls to near-undetectable levels between pulses
• Diurnal pattern: Strongest secretion during the first hours of sleep; additional pulses triggered by fasting, exercise, and stress

This pulsatility is functionally important — continuous vs. pulsatile GH exposure produces different gene expression profiles in the liver and different metabolic outcomes. This is a key consideration when comparing research peptides with different pharmacokinetic profiles (e.g., CJC-1295 without DAC preserves pulsatility; CJC-1295 with DAC elevates baseline GH levels).

GHRH Signalling In Detail

The GHRH Receptor

• Type: Class B G-protein coupled receptor (secretin receptor family)
• Location: Anterior pituitary somatotrophs (primary); also expressed in extrapituitary tissues
• G-protein coupling: Gs → adenylyl cyclase → cAMP → PKA

GHRH Receptor → GH Release

The complete intracellular cascade:

1. GHRH binds → GHRH-R conformational change → Gs activation
2. Gs activates adenylyl cyclase → cAMP increases
3. cAMP activates PKA → multiple downstream phosphorylation targets
4. Acute effect: PKA phosphorylates ion channels → Ca²⁺ influx → GH granule exocytosis
5. Chronic effect: PKA activates CREB (cAMP response element-binding protein) → GH gene transcription → new GH synthesis
6. Somatotroph proliferation: Chronic GHRH signalling promotes somatotroph cell division, maintaining the GH-producing cell population

GHRH Analog Peptides

Research peptides targeting this pathway include:

Somatostatin: The Brake

Somatostatin Receptors

Five somatostatin receptor subtypes (SST1-SST5) exist. On pituitary somatotrophs, SST2 and SST5 are the primary mediators of GH inhibition:

• G-protein coupling: Gi → inhibition of adenylyl cyclase → cAMP decrease
• Ion channel effects: K⁺ channel activation (hyperpolarisation) and Ca²⁺ channel inhibition
• Net effect: Directly opposes GHRH signalling at the cAMP level and prevents the Ca²⁺ influx required for GH granule exocytosis

The GHRH-Somatostatin Oscillation

The hypothalamus coordinates GHRH and somatostatin release in an alternating pattern:

• GH pulse: GHRH release increases while somatostatin release decreases → somatotrophs receive "go" signal
• GH trough: GHRH release decreases while somatostatin release increases → somatotrophs receive "stop" signal

This oscillation generates the characteristic pulsatile GH secretion pattern. Disruption of this oscillation (e.g., by continuous GHRH or continuous somatostatin) abolishes normal pulsatility.

The GHS/Ghrelin Pathway

The Third Input

The discovery of ghrelin and the GHS-R1a receptor added a third regulatory input to the GH axis:

• Ghrelin: 28-amino acid peptide produced primarily by gastric oxyntic cells; requires octanoyl modification for receptor binding
• GHS-R1a: Class A GPCR; expressed on pituitary somatotrophs and hypothalamic neurons
• Signalling: Gq/11 → PLC → IP3 + DAG → Ca²⁺ release + PKC activation

GHS Research Peptides

Why GHRH + GHS Produces Synergy

As detailed in our CJC-1295 and Ipamorelin synergy article:

• GHRH and GHS activate different G-proteins (Gs vs. Gq/11) and different second messenger systems (cAMP vs. IP3/Ca²⁺)
• GHRH primes GH synthesis; GHS triggers release of synthesised GH
• GHS partially overcomes somatostatin inhibition, creating a permissive environment for GHRH action
• The result is supra-additive GH release

Negative Feedback Loops

Short Loop: GH Feedback

• GH acts directly on the hypothalamus to stimulate somatostatin release
• GH may also suppress GHRH release (though this is less well characterised)
• This provides rapid feedback to prevent excessive GH secretion

Long Loop: IGF-1 Feedback

• GH stimulates hepatic IGF-1 production
• IGF-1 feeds back to both the hypothalamus (increasing somatostatin, decreasing GHRH) and the pituitary (direct inhibition of GH secretion)
• This is the primary long-term regulatory mechanism for maintaining GH/IGF-1 homeostasis

Implications for Research

Understanding feedback is critical for interpreting research results:

• Chronic GHRH or GHS administration will eventually upregulate feedback mechanisms, potentially blunting responses over time (tachyphylaxis)
• IGF-1 levels are a downstream biomarker of GH axis activity but reflect integrated GH exposure, not pulse characteristics
• The degree of feedback activation depends on the magnitude and pattern (pulsatile vs. continuous) of GH stimulation

Age-Related Changes

The GH axis undergoes significant changes with ageing ("somatopause"):

• GH pulse amplitude decreases by approximately 14% per decade after age 25
• Total 24-hour GH secretion decreases by ~50% between ages 20 and 60
• IGF-1 levels decline proportionally
• Somatostatin tone increases with age
• GHRH neuron number and activity decrease
• GHS-R1a expression may decrease

These age-related changes provide context for research on GHRH analogs and GHS compounds in ageing models — the rationale is restoration of youthful GH pulsatility rather than supraphysiological stimulation.

Frequently Asked Questions

What is the growth hormone axis? The growth hormone axis is the hypothalamic-pituitary system that regulates GH secretion, balancing stimulatory signals (GHRH and the ghrelin/GHS receptor) against the inhibitory hormone somatostatin, with downstream IGF-1 production and feedback. Research peptides such as GHRH analogs and GH secretagogues act on specific nodes of this network.

What is the difference between a GHRH analog and a GH secretagogue? GHRH analogs (for example tesamorelin and CJC-1295) act on the GHRH receptor via the Gs/cAMP pathway to drive GH synthesis and release. GH secretagogues (for example ipamorelin) act on the ghrelin receptor GHS-R1a via the Gq/calcium pathway, amplifying GH pulses and partially overcoming somatostatin. Because they use different pathways, combining them can produce a synergistic GH response in research models.

Why is pulsatile versus continuous GH release important in research? GH is normally secreted in discrete pulses, and pulsatile versus continuous exposure produces different downstream gene-expression and metabolic outcomes in animal models. This is why peptides with different pharmacokinetics — such as CJC-1295 with versus without DAC — are studied differently.

Are growth-hormone research peptides legal to buy in Australia? The GHRH analogs and secretagogues we supply are sold strictly as research chemicals for in-vitro laboratory use — not for human or animal consumption — and are not approved for human therapeutic use in Australia. Researchers are responsible for compliance with Therapeutic Goods Administration (TGA) regulations and their institution's protocols.

Does Australian Peptide Labs provide dosing protocols for these peptides? No. As these compounds are supplied for laboratory research only, we do not provide dosing or administration protocols. Our research library covers reconstitution and concentration calculations for in-vitro work.

References

1. Giustina, A. & Veldhuis, J.D "Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human." Endocrine Reviews, 1998. — PubMed: 9861545
2. Thorner, M.O. et al. "Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging." Recent Progress in Hormone Research, 1997. — PubMed: 9238854
3. Kojima, M. et al. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature, 1999. — PubMed: 10604470
4. Ho, K.Y. et al. "Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations." Journal of Clinical Endocrinology & Metabolism, 1987. — PubMed: 3782436

⚠️ Medical & Regulatory Disclaimer:
The information provided in this academic article is intended exclusively for educational and laboratory research purposes. It does NOT constitute medical advice. Compounds discussed are strictly for in-vitro research and development only, and are not intended for human consumption, veterinary use, or clinical treatment. Always adhere to Australian Therapeutic Goods Administration (TGA) regulations and your institution's ethical guidelines when handling research chemicals.